Weekly semaglutide lowered BMI in children aged 6 to under 12 with obesity: phase 3 trial
In a randomised, placebo-controlled trial in 167 children with obesity, weekly semaglutide reduced BMI by 13.5% at week 68, while BMI rose by 2.7% with placebo.

At a glance
- At week 68, BMI fell by 13.5% with semaglutide and rose by 2.7% with placebo (difference -16.2 percentage points).
- BMI category improved in 79% of children on semaglutide and 23% on placebo; 38% versus 2% moved below the obesity threshold.
- Gastrointestinal adverse events were the most common and were more frequent with semaglutide; 1 child stopped treatment because of them.
Key result
Semaglutide lowered BMI by 13.5% vs a 2.7% rise with placebo at week 68.
Change in BMI from baseline, Week 68
This report in under a minute
53 seconds. Free to use in your CME talks, with credit to Diabesity Rounds. Download the video · captions (SRT).
The study
This was a phase 3, double-blind, randomised, placebo-controlled trial (STEP Young) published in The New England Journal of Medicine. It enrolled children aged 6 to under 12 years with obesity. The authors note that once-weekly subcutaneous semaglutide is approved for obesity in adolescents and adults, but data in young children have been lacking.
A total of 167 children were randomised in a 2:1 ratio: 112 to once-weekly subcutaneous semaglutide and 55 to placebo. Treatment lasted 104 weeks, followed by a 7-week washout with no study drug. Both groups received counselling on lifestyle change. The primary end point was the percent change in body-mass index (BMI) from baseline to week 68. The confirmatory secondary end point was a reduction in BMI category at week 68. The trial was funded by Novo Nordisk.
What they found
At week 68, mean BMI fell by 13.5% with semaglutide and rose by 2.7% with placebo. The estimated between-group difference was -16.2 percentage points (95% CI, -19.4 to -12.9; P<0.001).
At week 104, BMI had fallen by 9.4% with semaglutide and risen by 8.4% with placebo (between-group difference, -17.8 percentage points; 95% CI, -22.2 to -13.3).
At week 68, BMI category improved in 79% of children on semaglutide and in 23% on placebo (odds ratio, 7.8; 95% CI, 3.5 to 17.6; P<0.001). BMI was below the obesity threshold (the 95th percentile for age and sex) in 38% of the semaglutide group and in 2% of the placebo group.
Adverse events occurred in 96% of children on semaglutide and in 93% on placebo. Gastrointestinal adverse events were the most common and were more frequent with semaglutide. They led to stopping treatment in 1 child in the semaglutide group.
How much weight to give it
This is a phase 3, double-blind, randomised, placebo-controlled trial, which is a strong design. The authors conclude that 68 weeks of semaglutide gave a significantly greater mean percent reduction in BMI than placebo. Treatment also continued to week 104, which adds some information on durability while on the drug.
There are limits to keep in mind. The trial is modest in size, with 167 children. The main outcomes are BMI change and BMI category, not longer-term health outcomes. The abstract does not report what happened to BMI during the 7-week washout after stopping treatment. It also does not give details on growth, puberty, mental health or the types of gastrointestinal events. The trial was funded by Novo Nordisk. The full paper should be read for these details.
For your clinic
This trial gives randomised evidence on semaglutide in an age group where, as the authors note, data have been lacking. Both groups received lifestyle counselling, so the results show the effect of semaglutide on top of lifestyle support, not instead of it.
The abstract does not support decisions on dose, duration or what happens after stopping. Gastrointestinal side effects were common, and almost all children in both groups reported some adverse event. Read the full paper before drawing practical conclusions for young children.
Source
Semaglutide for the Treatment of Obesity in Children 6 to <12 Years of Age.
Jastreboff AM, Harder-Lauridsen NM, Van Name M et al.. The New England journal of medicine. 16 November 2026
Teaching a session? Download this report as a slide (PNG, free to use with credit).
For registered medical practitioners. This report summarises published research and is not advice for individual patients. Read the full paper and current guidelines before changing practice. Found an error? Write to editor@diabesityrounds.com; see our corrections and editorial policy.
More on glp-1 and incretin drugs
- Phase 3 trial reports BMI changes with liraglutide 3.0 mg in children aged 6 to 11Trial registry · 17 November 2026
- Weekly ribupatide lowers body weight over 48 weeks in Chinese adults without diabetesRandomised trial · 17 November 2026
- SURMOUNT-ADOLESCENTS: tirzepatide lowered BMI by 18.5% in adolescents at 72 weeksRandomised trial · 17 November 2026
- CagriSema 1.7 mg and 1.0 mg each cut bodyweight more than placebo in REDEFINE 9Randomised trial · 16 November 2026
Go deeper
- CASPIAN Certificate in Obesity MedicineRegister interest for the next batch
- Beta Cell AcademyCME for doctors in Hyderabad
Today's Rounds, in your inbox at 8am
The day's reports each morning, and Weekend Rounds on Saturday. Free, no advertising.
Or follow on WhatsApp or Telegram (every report, as it is published), watch on YouTube, listen on Spotify or Apple Podcasts, or follow on LinkedIn. Not sure? Pick one.